Polypid Ltd (PYPD)
$3.54
Performance
- $3.54$3.61$3.54
0.0%
Downside
Day's Volatility :1.94%
Upside
1.94%
- $2.95$9.20$3.54
16.67%
Downside
52 Weeks Volatility :67.93%
Upside
61.52%
Returns
| Period | Polypid Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | -11.5% | 0.0% |
6 Months | -21.33% | 0.0% |
1 Year | -4.32% | 0.0% |
3 Years | -98.44% | -20.8% |
Highlights
Market Capitalization | 24.4M |
Book Value | $0.33 |
Earnings Per Share (EPS) | -8.76 |
Wall Street Target Price | 12.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -64.65% |
Return On Equity TTM | -496.62% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -21.9M |
Diluted Eps TTM | -8.76 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.14 |
EPS Estimate Next Year | -2.97 |
EPS Estimate Current Quarter | -1.3 |
EPS Estimate Next Quarter | -1.1 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 248.31%
Technicals Summary
Sell
Neutral
Buy
Polypid Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Polypid Ltd | 2.43% | -21.33% | -4.32% | -98.44% | -99.38% |
 Regeneron Pharmaceuticals, Inc. | -12.99% | 6.13% | 19.74% | 81.09% | 249.37% |
 Novo Nordisk A/s | -10.72% | -7.6% | 27.93% | 139.42% | 357.36% |
 Alnylam Pharmaceuticals, Inc. | 5.86% | 70.96% | 58.49% | 30.96% | 253.38% |
 Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 154.45% | 168.54% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Polypid Ltd | NA | NA | NA | -5.14 | -4.97 | -0.65 | NA | 0.33 |
Regeneron Pharmaceuticals, Inc. | 26.37 | 26.37 | 1.36 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.54 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Polypid Ltd | Buy | $24.4M | -99.38% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $109.8B | 249.37% | 26.37 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 357.36% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 253.38% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $115.8B | 168.54% | 32.84 | -4.74% |
Insights on Polypid Ltd
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.8% return, outperforming this stock by 57.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 31.0% return, outperforming this stock by 129.4%
Institutional Holdings
AIGH Capital Management, LLC
7.04%Rosalind Advisors, Inc.
6.13%Dafna Capital Management LLC
2.72%ADAR1 Capital Management LLC
1.53%Yelin Lapidot Holdings Management Ltd
0.16%Steward Partners Investment Advisory, LLC
0.11%
Company Information
polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid’s anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs' therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body’s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid’s pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e
Organization | Polypid Ltd |
Employees | 59 |
CEO | Ms. Dikla Czaczkes Akselbrad |
Industry | Health Technology |
Discover More
Kura Oncology Inc
$3.54
-1.25%
Rpar Risk Parity Etf
$3.54
-1.25%
Allianzim Us Large Cap Buffer10 Feb Etf
$3.54
-1.25%
Alterity Therapeutics Ltd
$3.54
-1.25%
Trueshares Structured Outcome (january) Etf
$3.54
-1.25%
Jianzhi Education Technology Group Company Ltd.
$3.54
-1.25%
Kura Sushi Usa Inc-class A
$3.54
-1.25%
Innovator S&p 500 Power Buff
$3.54
-1.25%
Anixa Biosciences, Inc.
$3.54
-1.25%